Company / CapEx per Share
ALNYLAM PHARMACEUTICALS, INC. CapEx per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest CapEx per Share
$0.45
FY2025
5-year range
$0.27 / $1.20
FY2021-FY2025
Trend
+66.6%
vs FY2024
Sector context
#28 of 192
Health Care
What the data says
ALNYLAM PHARMACEUTICALS, INC.'s capex per share of $0.45 is higher than 85% of companies in the Health Care sector (FY2025). CapEx per Share returned to growth in FY2025 after 3 years of decline, reaching $0.45.
Based on SEC 10-K filings.
0.45 in FY2025 with a 5-year CAGR of -16.7%. Top quartile in the Health Care sector.
Declined from $0.50 to $0.45 over the past 2 years.
Health Care sector context is included.
CapEx per Share over time
Growth rates
- 3-Year CAGR
- -8.1%
- 5-Year CAGR
- -16.7%
- 10-Year CAGR
- -
Sector benchmark
Top 15% in Health CareTop 15% of 192This company $0.45 Sector average $2.46
▼
-81.6% below sector average
Key checks
Key Insights
- In FY2025, capex per share increased 66.6% year-over-year.
- Ranks #28 out of 192 companies in the Health Care sector.
- Peak capex per share was recorded in FY2021.
- Lowest capex per share in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.37 (distress zone, below 1.8 threshold)
- Negative profit margin: -12.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | CapEx per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.45 | +66.6% |
| FY2024 | $0.27 | -45.7% |
| FY2023 | $0.50 | -14.3% |
| FY2022 | $0.59 | -51.4% |
| FY2021 | $1.20 | +6.4% |
| FY2020 | $1.13 | +9.8% |
| FY2019 | $1.03 | +59.0% |
| FY2018 | $0.65 | -43.7% |
| FY2017 | $1.15 | +52.6% |
| FY2016 | $0.75 | +389.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026